Bullish case
$45 to $60
More likely if Casdatifan shows compelling efficacy in kidney cancer trials, Domvanalimab delivers positive Phase 3 data in lung or GI cancers, and partnership revenues expand with BMS or AstraZeneca.
Arcus Biosciences Inc. research snapshot
RCUS AI Stock Analysis
RCUS AI stock analysis currently reads Arcus Biosciences as a clinical-stage biopharmaceutical company developing novel cancer immunotherapies, with a pipeline centered on Casdatifan (HIF-2a inhibitor), Domvanalimab (anti-TIGIT), and Zimberelimab (anti-PD-1). The analysis uses a scenario framework, not a certain price prediction. At the July 13, 2026 cutoff, the latest quote was $27.31, market capitalization was about $3.44 billion, and the main question was whether clinical data readouts, partnership execution, and cash runway can support the current valuation. This is informational research and not investment advice.
Current price
$27.31
Market cap
$3.44 billion
AI score
52 / 100
Rating
Speculative biotech with promising pipeline, pre-profit
Trend status
Strong uptrend from 52-week low near $7.91
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- B-level information richness. Arcus has SEC filings, analyst coverage from 10+ firms, active clinical trial disclosures, and observable partnership data. The largest gap is that future value depends on binary clinical catalysts, which public data can map but not predict.
- bias Check
- The main AI bias risk is over-weighting recent price momentum (stock up over 200% in the past year) when assessing business quality. The analysis separates clinical evidence from stock price action.
- ai Confidence
- Medium data confidence
- investment Certainty
- Low to medium. The business trajectory depends on clinical trial outcomes, regulatory decisions, and partnership economics, all of which carry inherent binary risk that no amount of data analysis can eliminate.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Arcus discovers and develops cancer therapies targeting immune checkpoint and hypoxia pathways. Revenue comes from collaboration payments, not product sales, and the company is not yet profitable. | Medium |
| Moat | The moat is potential, not proven. Arcus holds IP around HIF-2a, anti-TIGIT, CD73, and CD39 programs, but competitive positioning depends on clinical differentiation versus larger players like Merck, BMS, and Roche. | Low-medium |
| Management | Management has deep oncology drug development experience and has secured partnerships with AstraZeneca, BMS, and Gilead. Capital allocation discipline matters as cash burn continues. | Medium |
| Financial trend | TTM revenue of $236 million mainly from collaboration income. Net loss of -$369 million TTM reflects heavy R&D investment. Cash position of $822 million provides runway into key clinical catalysts. | Medium |
| Valuation | At 13x TTM revenue and 6.5x book value, valuation reflects pipeline potential rather than current earnings. The stock must deliver positive clinical data to justify the multiple. | Low-medium |
| Technical trend | RCUS has rallied sharply from a 52-week low near $7.91 to recent highs near $28.72. Momentum is strong but the stock is near the top of its range. | Medium |
| Risk level | High. Clinical trial failure, regulatory delay, competition from larger biopharma, cash burn, dilution risk, and binary catalyst dependence are all material risk factors. | High |
| AI confidence | Medium confidence for mapping the pipeline, financial position, and partnership structure. Lower confidence for predicting clinical trial outcomes or stock price reactions. | Medium data confidence |
| Investment certainty | Low to medium certainty. The business is pre-revenue from product sales and carries typical clinical-stage biotech binary risk. | Low-medium |
RCUS AI stock forecast
RCUS AI Stock Forecast Scenarios
The RCUS AI stock forecast uses scenario ranges around the $27.31 cutoff price rather than a point target. The bullish case requires positive clinical data for Casdatifan and Domvanalimab and sustained partnership support; the base case assumes mixed readouts with stock consolidating; the bearish case assumes clinical setbacks or financing concerns.
Base case
$20 to $32
More likely if clinical data are mixed but not negative, the company maintains its cash runway and partnership structure, and the stock trades within analyst consensus ranges.
Bearish case
$8 to $16
More likely if key trial results disappoint, a large partner withdraws, equity dilution is needed to extend cash runway, or the competitive landscape shifts against Arcus programs.
RCUS AI technical analysis
RCUS AI Technical Analysis
RCUS AI technical analysis starts from the $27.31 quote as of the July 13, 2026 data cutoff. Public technical sources showed the stock in a strong uptrend from its 52-week low, but approaching the upper end of its recent range. Because this static page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $27.31 | Quote as of the July 13, 2026 data cutoff from Yahoo Finance. |
| Near support | $22 to $24 | Recent consolidation zone and potential support area from prior price action. |
| Secondary support | $18 to $20 | Deeper support zone. A break below this level would weaken the technical setup significantly. |
| Near resistance | $28 to $29 | The 52-week high zone around $28.72. Breakout above this level with volume would be a bullish signal. |
| 50-day moving average | Requires live chart confirmation | Use current chart data before acting. The page does not fetch request-time market data. |
| 200-day moving average | Requires live chart confirmation | Long-term trend confirmation should be checked against a live chart or broker data. |
| Momentum | Strongly bullish, near overbought | The stock has rallied over 200% from 52-week lows. Momentum is strong but the stock may be short-term extended. |
| Volume | Average volume near 1.19 million shares | Liquidity is adequate for most position sizes. Watch for volume confirmation on breakouts. |
| Volatility | High | Biotech stocks can move sharply on clinical data releases. Position sizing should account for gap risk. |
| Invalidation | Close below $22 | A sustained close below the $22 support zone would suggest the uptrend is losing momentum. |
RCUS AI trading strategy
RCUS AI Trading Strategy Framework
The RCUS AI trading strategy is a rules-based research framework, not personalized advice. It combines pipeline stage awareness, technical confirmation, position sizing for binary risk, and clear catalyst monitoring.
Catalyst-driven setup
Identify upcoming clinical data readouts, regulatory decisions, and partnership announcements. Enter a research position ahead of catalysts with defined loss limits.
Biotech binary events can produce 30-50% moves. Position size must be small enough to survive a complete loss of the bet.
Trend-following setup
If RCUS holds above $24 support and breaks above $29 resistance with volume, momentum could extend. Confirm with rising moving averages and improving volume.
A failed breakout or close below support should invalidate the setup. Do not chase extended prices.
Fundamental monitor
Track Casdatifan and Domvanalimab clinical trial updates, partnership expansions, cash runway, quarterly R&D spend, and analyst coverage changes.
Reduce position if cash runway shortens without a financing plan, or if key partnership activity signals reduced commitment.
Investment research summary
Four-master Research Compression
Business essence
Arcus Biosciences discovers and develops cancer immunotherapies targeting immune checkpoint and hypoxia pathways, currently pre-revenue from product sales and funded by partnership income and equity financing.
Moat
Arcus holds intellectual property around HIF-2a inhibition, anti-TIGIT, CD73, and CD39 programs. Competitive differentiation depends on clinical data versus large biopharma programs from Merck, BMS, and Roche.
Munger risk inversion
The thesis can fail if Casdatifan or Domvanalimab clinical data disappoint, a partner like BMS or AstraZeneca withdraws, cash burn forces dilutive financing, or competing therapies reach the market first with better profiles.
Management
Led by experienced oncology drug developers. Management has secured high-value partnerships with AstraZeneca, BMS, and Gilead. Capital allocation and pipeline prioritization are key monitoring areas.
Industry trend
Cancer immunotherapy is a large and growing field. Arcus targets multiple pathways (HIF-2a, TIGIT, CD73, CD39) in indications with high unmet need, but competition from well-funded large pharma is intense.
Valuation and margin of safety
At 13x TTM revenue and no earnings, the stock prices in meaningful pipeline success. Safety margin is low given the binary nature of clinical-stage biotech investing.
Source-backed data
RCUS Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RCUS price | $27.31 close | Yahoo Finance quote snapshot | July 13, 2026 |
| Market capitalization | $3.44 billion, verified as $27.31 x 125.78 million shares | financial_rigor.py market cap verification and Yahoo Finance | July 13, 2026 |
| TTM revenue | $236 million | Yahoo Finance key statistics | July 13, 2026 |
| TTM net income | -$369 million | Yahoo Finance key statistics | July 13, 2026 |
| Cash and cash equivalents | $822 million | Yahoo Finance key statistics | July 13, 2026 |
| Enterprise value | $2.72 billion | Yahoo Finance | July 13, 2026 |
| Price to sales (TTM) | 13.17x | Yahoo Finance | July 13, 2026 |
| Analyst consensus | Average target $35.75, range $22 to $47 | Yahoo Finance analyst insights | July 13, 2026 |
| 52-week range | $7.91 to $28.72 | Yahoo Finance | July 13, 2026 |
| Beta (5Y monthly) | 0.84 | Yahoo Finance | July 13, 2026 |
| Valuation math | PE: negative (no earnings), PB: 6.55x, PS: 13.17x, ROE: -76% from financial_rigor.py | financial_rigor.py valuation verification | July 13, 2026 |
Frequently Asked Questions
Read the NVDA AI stock analysisView AAPL AI stock forecastExplore AI Stock PickerGenerate an AI trading strategy
This RCUS AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available data as of July 13, 2026 and can be wrong. Clinical-stage biotech investments carry a high risk of loss.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it